NO20061873L - Clastridium botulinum C3-eksotransferasesammensetning og fremgangsmate for a behandle tumorspredning - Google Patents
Clastridium botulinum C3-eksotransferasesammensetning og fremgangsmate for a behandle tumorspredningInfo
- Publication number
- NO20061873L NO20061873L NO20061873A NO20061873A NO20061873L NO 20061873 L NO20061873 L NO 20061873L NO 20061873 A NO20061873 A NO 20061873A NO 20061873 A NO20061873 A NO 20061873A NO 20061873 L NO20061873 L NO 20061873L
- Authority
- NO
- Norway
- Prior art keywords
- cell
- exotransferase
- compositions
- botulinum
- proliferation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 3
- 230000035755 proliferation Effects 0.000 abstract 2
- 241000193155 Clostridium botulinum Species 0.000 abstract 1
- 102000003939 Membrane transport proteins Human genes 0.000 abstract 1
- 108090000301 Membrane transport proteins Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009061 membrane transport Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Famrnasøytiske sammensetninger, som alle består av et cellepermeabelt fusjonsproteinkonjugat med en polypeptidbasert cellemembran-transportgruppe og en Clostridium botulinum C3-eksotransferaseenhet eller en funksjonell analog derav tilveiebringes. Sammensetningene er anvendbare for å forhindre eller inhibere ukontrollert proliferasjon, spredning og migrasjon av en metastatisk neoplastisk celle fra en kreft i et pattedyr. Sammensetningene kan alle påvirke eller stanse en kombinasjon av to eller flere av proliferasjon av tumorceller, migrasjon av tumorceller, angiogenese og sekresjon av en metalloproteinase fra tumorceller.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50616203P | 2003-09-29 | 2003-09-29 | |
US10/902,878 US20060134140A1 (en) | 2001-04-12 | 2004-08-02 | Compositions and methods for treating tumor spreading |
PCT/CA2004/001763 WO2005030248A1 (en) | 2003-09-29 | 2004-09-29 | Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061873L true NO20061873L (no) | 2006-06-29 |
Family
ID=34396295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061873A NO20061873L (no) | 2003-09-29 | 2006-04-27 | Clastridium botulinum C3-eksotransferasesammensetning og fremgangsmate for a behandle tumorspredning |
Country Status (13)
Country | Link |
---|---|
US (4) | US20060134140A1 (no) |
EP (1) | EP1667709A4 (no) |
JP (1) | JP2007506795A (no) |
KR (1) | KR20070051766A (no) |
CN (1) | CN1886154A (no) |
AU (1) | AU2004275449A1 (no) |
BR (1) | BRPI0414881A (no) |
CA (1) | CA2539694A1 (no) |
EA (1) | EA008824B1 (no) |
IL (1) | IL174632A0 (no) |
NO (1) | NO20061873L (no) |
NZ (1) | NZ546253A (no) |
WO (1) | WO2005030248A1 (no) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7795218B2 (en) | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
US7442686B2 (en) | 2001-04-12 | 2008-10-28 | Bioaxone Therapeutique Inc. | Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
ATE525085T1 (de) | 2004-09-23 | 2011-10-15 | Toxcure Inc | Behandlung von neoplasmen mit neurotoxin |
US8343929B2 (en) | 2004-09-23 | 2013-01-01 | Toxcure, Inc. | Treating neoplasms with neurotoxin |
MY142987A (en) * | 2005-06-08 | 2011-02-14 | Hayashibara Biochem Lab | Solution for tissue adhesion prevention and method for tissue adhesion prevention |
WO2008063972A2 (en) * | 2006-11-16 | 2008-05-29 | Sandisk Corporation | Controlled boosting in non-volatile memory soft programming |
US8486467B1 (en) * | 2007-09-20 | 2013-07-16 | Albert G. Prescott | Dermal filler and method of using same |
US20090252712A1 (en) * | 2008-03-07 | 2009-10-08 | Alseres Pharmaceuticals, Inc. | Chimeric c3-like rho antagonist bone therapeutic |
CA2744823C (en) | 2008-11-26 | 2015-07-21 | Toxcure, Inc. | Treating neoplasms with neurotoxin |
WO2010120931A2 (en) * | 2009-04-14 | 2010-10-21 | University Of Medicine And Dentistry Of New Jersey | E2f as a target for treatment of hormone refractory prostate cancer |
US20120207743A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases |
US20140086995A1 (en) * | 2011-04-12 | 2014-03-27 | Buddy D. Ratner | Polymer microsphere compositions for localized delivery of therapeutic agents |
RU2473367C1 (ru) * | 2011-11-22 | 2013-01-27 | Федеральное государственное унитарное предприятие "Научно-производственное объединение "Радиевый институт им. В.Г. Хлопина" | Способ изготовления стента для радиационной терапии злокачественных опухолей желчного протока |
CN108102945B (zh) * | 2012-04-27 | 2021-08-24 | 山东新创生物科技有限公司 | 包含戈氏梭菌的衍生细菌菌株的组合物及其使用方法 |
GB201505347D0 (en) * | 2015-03-27 | 2015-05-13 | Salupont Consulting Ltd | Sterilisation of s-nitrosothiols |
MX2019002835A (es) | 2016-09-13 | 2019-09-04 | Allergan Inc | Composiciones no proteínicas de toxina clostridial. |
US11324802B2 (en) | 2017-05-30 | 2022-05-10 | BioAxone BioSciences, Inc. | C3 fusion protein and methods of making and using thereof |
IT201800004220A1 (it) * | 2018-04-05 | 2019-10-05 | Dispositivo impiantabile per la somministrazione localizzata di farmaci, suoi usi e suo procedimento di fabbricazione. |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
ES2243995T3 (es) * | 1996-04-26 | 2005-12-01 | Beth Israel Deaconess Medical Center, Inc. | Antagonistas de interleucina-15. |
US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
JP4509395B2 (ja) * | 1999-04-27 | 2010-07-21 | 田辺三菱製薬株式会社 | 肝臓疾患の予防治療薬 |
US20020077283A1 (en) * | 2000-09-08 | 2002-06-20 | Sessa William C. | Caveolin peptides and their use as therapeutics |
DE10064195A1 (de) * | 2000-12-22 | 2002-07-11 | Migragen Ag | Verwendung einer Zusammensetzung zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens |
CA2342970A1 (en) * | 2001-04-12 | 2002-10-12 | Lisa Mckerracher | Fusion proteins |
CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
-
2004
- 2004-08-02 US US10/902,878 patent/US20060134140A1/en not_active Abandoned
- 2004-09-29 EA EA200600687A patent/EA008824B1/ru not_active IP Right Cessation
- 2004-09-29 WO PCT/CA2004/001763 patent/WO2005030248A1/en active Application Filing
- 2004-09-29 NZ NZ546253A patent/NZ546253A/en unknown
- 2004-09-29 KR KR1020067008338A patent/KR20070051766A/ko not_active Application Discontinuation
- 2004-09-29 JP JP2006529512A patent/JP2007506795A/ja active Pending
- 2004-09-29 EP EP04786681A patent/EP1667709A4/en not_active Withdrawn
- 2004-09-29 AU AU2004275449A patent/AU2004275449A1/en not_active Abandoned
- 2004-09-29 BR BRPI0414881-9A patent/BRPI0414881A/pt not_active IP Right Cessation
- 2004-09-29 CA CA002539694A patent/CA2539694A1/en not_active Abandoned
- 2004-09-29 CN CNA2004800353328A patent/CN1886154A/zh active Pending
- 2004-09-29 US US10/573,658 patent/US20080020000A1/en not_active Abandoned
-
2006
- 2006-03-29 IL IL174632A patent/IL174632A0/en unknown
- 2006-04-27 NO NO20061873A patent/NO20061873L/no not_active Application Discontinuation
-
2008
- 2008-12-08 US US12/329,918 patent/US20090142325A1/en not_active Abandoned
-
2009
- 2009-03-11 US US12/402,352 patent/US20090285833A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080020000A1 (en) | 2008-01-24 |
NZ546253A (en) | 2009-03-31 |
US20090285833A1 (en) | 2009-11-19 |
US20060134140A1 (en) | 2006-06-22 |
AU2004275449A1 (en) | 2005-04-07 |
CA2539694A1 (en) | 2005-04-07 |
IL174632A0 (en) | 2006-08-20 |
CN1886154A (zh) | 2006-12-27 |
WO2005030248A1 (en) | 2005-04-07 |
EA200600687A1 (ru) | 2006-10-27 |
BRPI0414881A (pt) | 2006-12-12 |
EP1667709A1 (en) | 2006-06-14 |
EP1667709A4 (en) | 2009-08-26 |
US20090142325A1 (en) | 2009-06-04 |
JP2007506795A (ja) | 2007-03-22 |
EA008824B1 (ru) | 2007-08-31 |
KR20070051766A (ko) | 2007-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061873L (no) | Clastridium botulinum C3-eksotransferasesammensetning og fremgangsmate for a behandle tumorspredning | |
DK1210411T3 (da) | Sammensætninger og fremgangsmåder til forbedret celledyrkning | |
ATE499098T1 (de) | Verwendung von parp-1-hemmern | |
DK1379671T3 (da) | Fremgangsmåder til dyrkning af circovirus | |
DK1044197T3 (da) | Piperidinylsubstituerede pyridylalkan-, -alken- og -alkyncarboxamider som cytostatiske midler og immunosuppressive midler | |
ME00804B (me) | Anti-alpha v beta 6 antitela | |
PT1017692E (pt) | 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep) | |
RS54149B1 (en) | COMPOSITIONS AND PROCEDURES IN VITRO AND IN VIVO, TARGETED MEDICINAL RELEASE IN Mammalian cells via intact minicells derived from bacteria | |
YU86901A (sh) | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama | |
ATE459653T1 (de) | Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen | |
NO20082381L (no) | Bispesifikke ligander med bindingsspesifisitet til celleoverflate mal og fremgangsmater for anvendelse derav | |
DE60143517D1 (de) | Wiederherstellung der gelenken mit mesenchymalen stammzellen | |
FI964033A0 (fi) | Menetelmiä sairauden hoitamiseksi käyttäen Sertoli-soluja ja allografteja tai ksengrafteja | |
ATE364695T1 (de) | Gekürzte lösliche typ-i-rezeptoren für tumor- nekrose-faktor | |
DE602005026962D1 (de) | Arylcarboxamide und ihre verwendung als antitumormittel | |
WO2007070372A3 (en) | Compositions and methods for inhibiting cellular proliferation | |
DK1773420T3 (da) | Anvendelse af gingivale fibroblaster til vaskulær celleterapi | |
DE60017141D1 (de) | Replikationskompetente anti-tumor vektoren | |
ATE326985T1 (de) | Lyophilisierte pharmazeutische zusammensetzung von propofol | |
DE60019894D1 (de) | Phenantrhridin-n-oxides mit pde-iv hemmender wirkung | |
ATE264247T1 (de) | Transportweiche für plattenmaterial-förderstrecke,insbesondere flachglas-förderstrecke | |
AR023582A1 (es) | Polinucleotidos de npr1 de maiz y metodos de uso de los mismos | |
CL2009001972A1 (es) | Polipeptido aislado que presenta actividad citoquinina oxidasa, construccion molecular y celula huesped que comprenden el acido nucleoico codificante para dicha proteina, y metodo para modular los niveles de citoquininas en plantas. | |
BRPI0409575A (pt) | anticorpos especìficos às células endoteliais e usos dos mesmos | |
ATE529108T1 (de) | Zellmigrationsmodulierende verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |